BioPharmSignal logoBioPharmSignal

Biotech News

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Delcath Systems (DCTH)Delcath Systems2026-06-25 13:46 ESTConference / presentation

QUEENSBURY, N.Y. --(BUSINESS WIRE)--May 12, 2026-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the H.C.

Open original release

Related news

DCTHDelcath Systems2026-06-25 13:46 EST

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

DCTHDelcath Systems2026-06-25 13:46 EST

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

DCTHDelcath Systems2026-06-25 13:46 EST

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

DCTHDelcath Systems2026-06-25 13:46 EST

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

DCTHDelcath Systems2026-06-25 13:46 EST

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

DCTHDelcath Systems2026-06-25 13:46 EST

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DCTHDelcath Systems2026-06-25 13:46 EST

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

DCTHDelcath Systems2026-06-25 13:46 EST

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

DCTHDelcath Systems2026-06-25 13:46 EST

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

DCTHDelcath Systems2026-06-25 13:46 EST

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

View all latest news

Delcath Systems

Delcath Systems is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

DCTHDelcath Systems2026-06-26 06:01 EST

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

DCTHDelcath Systems2026-06-26 06:01 EST

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

DCTHDelcath Systems2026-06-26 06:01 EST

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

DCTHDelcath Systems2026-06-26 06:01 EST

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

DCTHDelcath Systems2026-06-26 06:01 EST

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States